je.st
news
Tag: merck announces
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
2013-03-07 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role since 2003. To ensure a seamless transition, Dr. Perlmutter and Dr. Kim will work closely together for an initial period, after which Dr. Language: English Contact HTML: MerckMedia Contacts:Steven Cragle, 908-423-3461orInvestor Contacts:Alex Kelly, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Announces Second-Quarter 2013 Dividend
2013-02-26 20:29:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.43 per share on the companys common stock for the second quarter of 2013. Payment will be made on Apr. 5, 2013, to stockholders of record at the close of business on Mar. 15, 2013. About Merck Language: English Contact HTML: MerckMedia:Ron Rogers, 908-423-6449orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces dividend
Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
2013-02-01 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46 2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact from Foreign Exchange Full-Year and Fourth-Quarter Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS and ZOSTAVAX Offset the Decline in SINGULAIR Sales Following Patent Expiry in the United States Provides Update on Odanacatib Program; Now Anticipates Filing in 2014 2013 Full-Year Non-GAAP EPS Target of $3.60 to $3.70, Excluding Certain Items; GAAP EPS Range of $2.03 to $2.26 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012. Language: English Contact HTML: MerckMedia Contacts:Ron Rogers, 908-423-6449Steve Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
2013-01-07 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDAs review to be completed in the first half of 2013. Language: English Contact HTML: MerckMedia Contacts:Pam Eisele, 908-423-5042Lainie Keller, 908-423-4187orInvestor Contact:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
drug
acceptance
injection
Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets
2013-01-02 22:45:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine. The updated NDA was deemed complete for review after Merck submitted additional data in response to the FDAs Complete Response Letter issued last year. Language: English Contact HTML: MerckMedia:Pamela Eisele, 908-423-5042orSkip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
drug
announces
tablets
Sites : [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »